Section of Patient Centred Outcomes Research, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Department of Surgery, St. Joseph's Healthcare, McMaster University, Hamilton, CA, USA.
Eur J Cardiothorac Surg. 2018 Jul 1;54(1):122-126. doi: 10.1093/ejcts/ezx483.
The objective of this study was to evaluate the performance of 3 thoracic surgery centres using the Eurolung risk models for morbidity and mortality.
This was a retrospective analysis performed on data collected from 3 academic centres (2014-2016). Seven hundred and twenty-one patients in Centre 1, 857 patients in Centre 2 and 433 patients in Centre 3 who underwent anatomical lung resections were analysed. The Eurolung1 and Eurolung2 models were used to predict risk-adjusted cardiopulmonary morbidity and 30-day mortality rates. Observed and risk-adjusted outcomes were compared within each centre.
The observed morbidity of Centre 1 was in line with the predicted morbidity (observed 21.1% vs predicted 22.7%, P = 0.31). Centre 2 performed better than expected (observed morbidity 20.2% vs predicted 26.7%, P < 0.001), whereas the observed morbidity of Centre 3 was higher than the predicted morbidity (observed 41.1% vs predicted 24.3%, P < 0.001). Centre 1 had higher observed mortality when compared with the predicted mortality (3.6% vs 2.1%, P = 0.005), whereas Centre 2 had an observed mortality rate significantly lower than the predicted mortality rate (1.2% vs 2.5%, P = 0.013). Centre 3 had an observed mortality rate in line with the predicted mortality rate (observed 1.4% vs predicted 2.4%, P = 0.17). The observed mortality rates in the patients with major complications were 30.8% in Centre 1 (versus predicted mortality rate 3.8%, P < 0.001), 8.2% in Centre 2 (versus predicted mortality rate 4.1%, P = 0.030) and 9.0% in Centre 3 (versus predicted mortality rate 3.5%, P = 0.014).
The Eurolung models were successfully used as risk-adjusting instruments to internally audit the outcomes of 3 different centres, showing their applicability for future quality improvement initiatives.
本研究旨在使用 Eurolung 风险模型评估 3 家胸外科中心的发病率和死亡率。
这是一项回顾性分析,对 3 家学术中心(2014-2016 年)收集的数据进行了分析。中心 1 分析了 721 例解剖性肺切除术患者,中心 2 分析了 857 例患者,中心 3 分析了 433 例患者。使用 Eurolung1 和 Eurolung2 模型预测风险调整后的心肺发病率和 30 天死亡率。在每个中心内比较观察到的和风险调整后的结果。
中心 1 的观察发病率与预测发病率相符(观察发病率 21.1%比预测发病率 22.7%,P=0.31)。中心 2 的表现优于预期(观察发病率 20.2%比预测发病率 26.7%,P<0.001),而中心 3 的观察发病率高于预测发病率(观察发病率 41.1%比预测发病率 24.3%,P<0.001)。与预测死亡率相比,中心 1 的观察死亡率更高(3.6%比 2.1%,P=0.005),而中心 2 的观察死亡率显著低于预测死亡率(1.2%比 2.5%,P=0.013)。中心 3 的观察死亡率与预测死亡率相符(观察死亡率 1.4%比预测死亡率 2.4%,P=0.17)。在有主要并发症的患者中,中心 1 的观察死亡率为 30.8%(预测死亡率为 3.8%,P<0.001),中心 2 为 8.2%(预测死亡率为 4.1%,P=0.030),中心 3 为 9.0%(预测死亡率为 3.5%,P=0.014)。
Eurolung 模型成功地用作 3 个不同中心的风险调整工具,以内部审核其结果,显示了它们在未来质量改进计划中的适用性。